Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A Mereo BioPharma Group Filed by: EcoR1 Capital, LLC

August 14, 2026 12:57 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: These Ordinary Shares are held through 1,000,000 American Depositary Shares of the Issuer, each representing 5 Ordinary Shares. Percentage calculated based on 798,093,044 Ordinary Shares outstanding on May 11, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: These Ordinary Shares are held through 1,000,000 American Depositary Shares of the Issuer, each representing 5 Ordinary Shares. Percentage calculated based on 798,093,044 Ordinary Shares outstanding on May 11, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: These Ordinary Shares are held through 946,550 American Depositary Shares of the Issuer, each representing 5 Ordinary Shares. Percentage calculated based on 798,093,044 Ordinary Shares outstanding on May 11, 2026, as reported in the Form 10-Q filed by the Issuer for the quarterly period ended March 31, 2026.


SCHEDULE 13G



EcoR1 Capital, LLC
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:08/14/2026
Oleg Nodelman
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:08/14/2026
EcoR1 Capital Fund Qualified, L.P.
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:08/14/2026
Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

ATTACHMENTS / EXHIBITS

ex991.htm

Categories

SEC Filings